A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?

[1]  C. Rapezzi,et al.  COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm? , 2020, Basic Research in Cardiology.

[2]  Kasra Kolahdouzan,et al.  Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects? , 2020, Journal of medical virology.

[3]  C. Tondini,et al.  A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab , 2020, Journal of Thoracic Oncology.

[4]  R. Lu,et al.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens. , 2020, JAMA.

[5]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[6]  S. Bozinovski,et al.  G-CSFR antagonism reduces neutrophilic inflammation during pneumococcal and influenza respiratory infections without compromising clearance , 2019, Scientific Reports.

[7]  A. Sica,et al.  Myeloid suppressor cells in cancer and autoimmunity. , 2017, Journal of autoimmunity.

[8]  A. Spittler,et al.  GM-CSF Down-Regulates TLR Expression via the Transcription Factor PU.1 in Human Monocytes , 2016, PloS one.

[9]  Bin Zhang,et al.  Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer , 2014, Journal of immunology research.

[10]  J. Hamilton,et al.  Functions of granulocyte-macrophage colony-stimulating factor. , 2005, Critical reviews in immunology.